GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Daxor Corp (NAS:DXR) » Definitions » Scaled Net Operating Assets

Daxor (DXR) Scaled Net Operating Assets : 1.15 (As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Daxor Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Daxor's operating assets for the quarter that ended in Dec. 2023 was $34.87 Mil. Daxor's operating liabilities for the quarter that ended in Dec. 2023 was $0.10 Mil. Daxor's Total Assets for the quarter that ended in Jun. 2023 was $30.36 Mil. Therefore, Daxor's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 1.15.

Daxor Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Daxor's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(34.869-0.103)/30.261
=1.15

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Balance Sheet Cash And Cash Equivalents
=34.869 - 0
=34.869

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=0.859 - 0.756 - 0
=0.103

Daxor's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Jun. 2023 )
=(34.869-0.103)/30.359
=1.15

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Balance Sheet Cash And Cash Equivalents
=34.869 - 0
=34.869

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=0.859 - 0.756 - 0
=0.103

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daxor Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Daxor's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Daxor (DXR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Daxor Corp (NAS:DXR) » Definitions » Scaled Net Operating Assets
Comparable Companies
OMIC MLSS UEEC RVP POCI FEMY BNGO EKSO PDEX NEPH ISRG XPAR:EL BDX TSE:7741 XSWX:ALC OCSE:COLO B RMD WST XPAR:DIM TSE:4543
Traded in Other Exchanges
DX5:Germany
Address
109 Meco Lane, Oak Ridge, TN, USA, 37830
Website
https://www.daxor.com
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Executives
Robert J Michel officer: CHIEF FINANCIAL OFFICER C/O ASTA FUNDING, INC., 210 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Michael Richard Feldschuh director 71 GRAND STREET #2, NEW YORK NY 10013
Joy S. Goudie director 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Caleb Desrosiers director DAXOR CORPORATION, 109 MECO LANE, OAK RIDGE TN 37830
Henry D. Cremisi director 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Edward Feuer director 2 WALL STREET, 10TH FLOOR, NEW YORK NY 10005
Soren Thompson officer: V.P./BUSINESS DEVELOPMENT 180 CENTRAL PARK SOUTH, APT. 805, NEW YORK NY 10019
Jonathan Adam Feldschuh director, officer: CHIEF SCIENTIFIC OFFICER DAXOR CORPORATION, 350 5TH AVENUE, SUITE 4740, NEW YORK NY 10118
Joseph Feldschuh officer: President 615 W. 252ND STREET, BRONX NY 10471
Estate Of Joseph Feldschuh other: FOUNDER 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Diane Marie Meegan officer: Corporate Secretary 259 NEW YORK AVENUE, JERSEY CITY NJ 07307
Bernhard Saxe director 6805 WILD ROSE COURT, SPRINGFIELD VA 25152
Robert Willens director 200 EAST 74TH ST APT 18C, NEW YORK NY 10021
Philip Nordan Hudson director P.O. BOX 160892, SAN ANTONIO TX 78280-3092
Everis Engstrom officer: Vice President 3244 BLACK FOX ROAD, WASHBURN TN 37888